Øystein Rekdal, CEO in Lytix Biopharma, gave a short update on recent research showing that cancer patients with high tumor heterogeneity respond less to immune checkpoint inhibitors than cancer patients with low tumor heterogeneity.

Rekdal also presented how Lytix Biopharma`s LTX-315 can evoke tumor-specific immune responses in cancer patients with non-inflamed and heterogenous tumors and therefore is ideal to be used in combination therapies for this subpopulation of cancer patients.

Read more about ESMO